Lanadelumab prophylaxis improved patient and caregiver quality of life scores, changing how pediatric patients manage and predict hereditary angioedema attacks, HCPLive reported.
Eleven caregivers reported on 13 pediatric patients receiving long-term treatment. The mean age at which patients began lanadelumab was 8.9 years, and they underwent treatment for an average duration of 3.7 years.
On a 5-point scale where 1 indicated poor and 5 indicated excellent, caregiver-perceived patient quality of life rose from a mean of 2.2 before lanadelumab to 4.7 during the current treatment period. Caregiver-perceived caregiver quality of life climbed from 1.9 to 4.5.
Workplace and Daily Activity Impact
During the current treatment period, 69% of caregivers reported no impact of their child’s hereditary angioedema on work or daily activities. Before lanadelumab, only 23% of caregivers reported no work impact and 8% reported no daily activity impact.
As Lumry pointed out, 68% of caregivers experienced the need to request flexibility, quit their jobs, or implement other changes prior to their child starting prophylaxis.
Before lanadelumab, between 30% and 45% of caregivers experienced disruptions in family time, household chores, and errands, whereas no such impacts were reported while on treatment. The proportion of caregivers reporting impaired sleep fell from 85% before treatment to 31% during treatment.
PedsQL scores show improved family functioning and activities
PedsQL-FIM scores during treatment averaged 92 for family functioning and 90 for daily activities. For patients aged 5 to 7 years, average PedsQL total scores were 68.5, while those aged 8 to 12 years scored 91, and patients aged 13 to 18 years reached 84.
Reported impact on recreational activities dropped from 62% to 8%, matching an identical shift for work responsibilities.
“The study provides a really great multidimensional assessment of the broader impact of this very effective treatment in pediatric patients and in their caregivers,” said Lumry when presenting the findings.
Communication and worry about attacks remain stable
Two specific domains of the family impact module did not change significantly during the evaluation. Communication and worry about unpredictable attacks remained stable despite overall improvements.
Lumry noted these specific metrics showed no significant change. The findings were presented at the American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting in Phoenix, Arizona, detailing real-world outcomes from phase 3 SPRING study data.
Common Questions About Pediatric Hereditary Angioedema Treatment
What was the average age of patients when starting lanadelumab?
On average, individuals commenced lanadelumab at 8.9 years of age and maintained therapy for a mean span of 3.7 years.
How many caregivers reported impaired sleep before treatment versus during treatment?
The proportion of caregivers reporting impaired sleep fell from 85% before treatment to 31% during treatment.
Which specific family impact domains showed no significant change with treatment?
Communication and worry about unpredictable attacks did not change significantly, according to Lumry.
Keep reading